Is Enovis Corporation (ENOV) a High-Growth, Under-Valued Stock?
Key takeaways
- Is Enovis Corporation (ENOV) a High-Growth, Under-Valued Stock?
- In its first-quarter 2026 investor letter, American Century Investments Small Cap Value Fund highlighted Enovis Corporation (NYSE:ENOV).
- American Century Investments Small Cap Value Fund stated the following regarding Enovis Corporation (NYSE:ENOV) in its Q1 2026 investor letter:
Is Enovis Corporation (ENOV) a High-Growth, Under-Valued Stock? Soumya Eswaran Tue, June 9, 2026 at 8:25 PM GMT+7 2 min read ENOV ^RUT American Century Investments, an investment management company, released its first-quarter 2026 investor letter for the “American Century Investments Small Cap Value Fund.” A copy is available to download here. Equity markets encountered challenges during the quarter, initially due to fears of AI disruption and later due to the conflict in Iran. The Fund s Investor Class returned 3.85% for the quarter, outperforming a 4.96% return for the Russell 2000 Value Index. While the Industrial and Materials sectors underperformed, the exposure to Energy positively impacted relative performance. The portfolio focuses on investing in small-cap companies with undervalued quality and earnings potential. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, American Century Investments Small Cap Value Fund highlighted Enovis Corporation (NYSE:ENOV). Enovis Corporation (NYSE:ENOV) is a leading medical technology company specializing in the development of clinically differentiated solutions. On June 8, 2026, Enovis Corporation (NYSE:ENOV) closed at $23.68 per share. One-month return of Enovis Corporation (NYSE:ENOV) was -8.89%, and its shares lost 29.42% over the past 52 weeks. Enovis Corporation (NYSE:ENOV) has a market capitalization of $1.36 billion.
American Century Investments Small Cap Value Fund stated the following regarding Enovis Corporation (NYSE:ENOV) in its Q1 2026 investor letter: